Literature DB >> 8991507

Pathways of glycosphingolipid biosynthesis in SW13 cells in the presence and absence of vimentin intermediate filaments.

B K Gillard1, R G Harrell, D M Marcus.   

Abstract

We reported previously that the incorporation of sugars into glycosphingolipids (GSL) is diminished in SW13 cells that lack a vimentin intermediate filament (IF) network (vim-) compared to vim+ cells. To further analyze the nature of this abnormality, we double-labeled cells with 3H-serine and 14C-sugars. There was no difference between vim+ and vim- cells in the incorporation of serine into GSL, although the usual difference in sugar incorporation was observed. This indicated that the defect in vim- cells was not in the incorporation of sugars into ceramide synthesized de novo by acylation of sphinganine (pathway 1). Sugars can also be incorporated into ceramide synthesized from sphingosine that is derived from catabolism of sphingolipids (pathway 2), and into GSL that recycle through the Golgi apparatus from endosomes (pathway 3). The amount of galactose and glucosamine incorporated into GSL in these three pathways was analyzed by the use of two inhibitors of sphingolipid biosynthesis. beta-Chloroalanine inhibits the de novo synthesis of sphinganine (pathway 1), and fumonisin B1 inhibits the acylation of sphinganine and sphingosine (pathways 1 and 2). We were surprised to observe that in both vim+ and vim- cells only 20-40% of sugar incorporation into GSL took place in pathway 1, and 60-80% of sugar incorporation took place in the recycling pathways. Moreover, in contrast to larger GSL, GlcCer was not synthesized in pathway 3. Our observations indicate that vimentin IF facilitate the recycling of GSL and sphingosine, and that the differences between vim+ and vim- cells are predominantly in pathways 2 and 3. Furthermore, although it is generally believed that virtually all GSL are synthesized in the de novo pathway, these data indicate that the recycling pathways predominate in the incorporation of sugars into GSL in SW13 cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8991507     DOI: 10.1093/glycob/6.1.33

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  9 in total

1.  Predominance of the acylation route in the metabolic processing of exogenous sphingosine in neural and extraneural cells in culture.

Authors:  L Riboni; R Bassi; A Prinetti; P Viani; G Tettamanti
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

2.  Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs).

Authors:  Roger Sandhoff; Konrad Sandhoff
Journal:  Adv Neurobiol       Date:  2023

Review 3.  Sphingolipids and cell signalling.

Authors:  P Fredman
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 4.  Ganglioside/glycosphingolipid turnover: new concepts.

Authors:  G Tettamanti
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 5.  Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis.

Authors:  R T Riley; E Enongene; K A Voss; W P Norred; F I Meredith; R P Sharma; J Spitsbergen; D E Williams; D B Carlson; A H Merrill
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

6.  Reevaluating the effect of Brefeldin A (BFA) on ganglioside synthesis: the location of GM2 synthase cannot be deduced from the inhibition of GM2 synthesis by BFA.

Authors:  W W Young; M L Allende; E Jaskiewicz
Journal:  Glycobiology       Date:  1999-07       Impact factor: 4.313

7.  Variations of ganglioside biosynthetic pathways in the phenotype conversion from myofibroblasts to lipocytes in murine hepatic stellate cell line.

Authors:  Aline B de Aguirres; Paola A Mello; Claudia M B Andrade; Ana Carolina Breier; Rogério Margis; Regina M Guaragna; Radovan Borojevic; Fátima C R Guma; Vera M T Trindade
Journal:  Mol Cell Biochem       Date:  2007-04-18       Impact factor: 3.842

8.  My career as an immunoglycobiologist.

Authors:  Donald M Marcus
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2013       Impact factor: 3.493

9.  Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.

Authors:  Ravshan Burikhanov; Vitaliy M Sviripa; Nikhil Hebbar; Wen Zhang; W John Layton; Adel Hamza; Chang-Guo Zhan; David S Watt; Chunming Liu; Vivek M Rangnekar
Journal:  Nat Chem Biol       Date:  2014-09-14       Impact factor: 15.040

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.